Natori Y, et al. - Considering the suboptimal immunogenicity of annual standard-dose (SD) influenza vaccine in solid organ transplant recipients (SOTRs), researchers investigated if influenza vaccine that contains higher doses of antigens may lead to greater immunogenicity in this population. They performed a randomized, double-blind trial to compare the safety and immunogenicity of the 2016–2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) influenza vaccine in adult SOTRs. Compared to SD vaccine, HD vaccine demonstrated significantly better immunogenicity in these adults and thus could be the preferred influenza vaccine for this population.